

Personalized Medicine - A Global Market Overview

<https://marketpublishers.com/r/PB5DCD6A2A8EN.html>

Date: August 2012

Pages: 350

Price: US\$ 3,600.00 (Single User License)

ID: PB5DCD6A2A8EN

Abstracts

Description:

Personalized Medicine can mean a lot of things to a lot of people. For some, it may relate to doctors having knowledge about their case history and the treatment received, which is a morale boosting factor, since everybody wants caregivers who can comprehend an individual's problems. The day is not very far when this level of personal or individual understanding between a patient and a doctor would be much deeper than hitherto anticipated. The coming decade is expected to witness an increase in the use of companion diagnostics and personalized medicines, with pricing incentives and efficiency improvement propelling the market. Current market leaders with diagnostic divisions focusing on biomarker identification would be at an advantage.

This report review, analyze and projects the personalized medicine market for global and the regional markets including the United States, Europe and Rest of World. The market numbers illustrated in this report only represent the market exclusively for the product segments and technologies enunciated above. The market, in this report, does not include the associated hardware equipment or software technologies that are used to manage patient data. The study includes recent and current trends related to technology and the market along with the key industry developments.

The market for personalized medicine product types analyzed in this study includes Targeted Biologics, Proteomics & Genomics, Genetically Modified (GM) Products, Wellness & Disease Management, Other Molecular Diagnostics and Self/Other Diagnostics. The report also includes the market analysis for application technologies of personalized medicine – Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other Technologies. The report analyses the global market in terms of USD Million.

This 350 page global market report includes 43 charts (includes a data table and graphical representation for each chart), supported with meaningful and easy to understand graphical presentation, of the market. The statistical tables represent the data for the global market by geographic region, product type and application technology. The report covers the brief business profiles of 56 key global players and 77 major players across the United States – 45; Europe – 24; and Rest of World – 8. The report also provides the listing of the companies engaged in research and development, manufacturing, processing, supplies and distribution of personalized. Also enlisting the academic institutions engages in personalized medicine, the global list covers the addresses, contact numbers and the website addresses of 395 companies.

Contents

PART A: GLOBAL MARKET PERSPECTIVE

1. INTRODUCTION

1.1 Product Outline

- 1.1.1 Personalized Medicine's Influence on Large Scale Studies
- 1.1.2 Gazing into the Crystal Ball: What the Future Holds for Personalized Medicine
- 1.1.3 Ramifications of Personalized Medicine for Healthcare Systems
 - 1.1.3.1 Pharmaceutical Industry
 - 1.1.3.2 Diagnostics Industry
 - 1.1.3.3 Insurers
 - 1.1.3.4 Physicians
 - 1.1.3.5 Government Agencies
 - 1.1.3.6 Patients
- 1.1.4 Analysis of Personalized Medicine by Segment
 - 1.1.4.1 Targeted Biologics
 - 1.1.4.1.1 Overview
 - 1.1.4.1.2 Targeted Biologics for Breast Cancer: An Illustration
 - 1.1.4.1.2.1 Targeted Biologic Therapy for Breast Cancer
 - 1.1.4.2 Proteomics & Genomics
 - 1.1.4.2.1 Proteomics
 - 1.1.4.2.1.1 A Complex Problem
 - 1.1.4.2.1.2 Post-Translational Modifications
 - 1.1.4.2.1.3 Phosphorylation
 - 1.1.4.2.1.4 Ubiquitination
 - 1.1.4.2.1.5 Other Modifications
 - 1.1.4.2.1.6 Inadequacies in Proteomics Studies
 - 1.1.4.2.1.7 Proteomics in Practical Applications
 - 1.1.4.2.2 Genomics
 - 1.1.4.2.2.1 Pharmacogenomics
 - 1.1.4.3 Genetically Modified (GM) Products
 - 1.1.4.3.1 The Genetic Engineering Process
 - 1.1.4.3.1.1 Applications of Genetic Engineering
 - 1.1.4.4 Wellness & Disease Management
 - 1.1.4.4.1 Wellness Defined
 - 1.1.4.4.1.1 The Ten Dimensions of Wellness
 - 1.1.4.4.2 Disease Management Defined

1.1.4.5 Molecular Diagnostic Technologies

1.1.4.5.1 DNA Sequencing

1.1.4.5.2 Biochips and Microarrays

1.1.4.5.2.1 Personalized Medicine Development Using DNA Biochip Technology

1.1.4.5.2.2 Protein Biochips' Role in Personalized Medicine

1.1.4.5.3 Cytogenetics

1.1.4.5.3.1 Personalized Medicine Based on Molecular Cytogenetics

1.1.4.5.3.2 Personalized Medicine Based on Cytomics

1.1.4.5.4 Single Nucleotide Polymorphism (SNP) Genotyping

1.1.4.5.4.1 Technologies for SNP Analysis

1.1.4.5.4.2 Applications of SNPs Pertinent to Personalized Medicine

1.1.4.5.5 Haplotyping

1.1.4.5.5.1 HapMap Project

1.1.4.5.5.2 HapMap for Predicting Drug Response

1.1.4.5.6 Application of Proteomics in Molecular Diagnosis

1.1.4.5.6.1 Proteomic and Genomic Approaches in Personalized Medicine

Compared

1.1.4.5.7 Gene Expression Profiling

1.1.4.5.8 Personalized Medicine and Molecular Imaging

1.1.4.5.9 Diagnostics Based On Glycomics

1.1.4.5.10 Combining Diagnostics and Therapeutics

1.1.4.5.11 Point-Of-Care (POC) Diagnosis

1.1.4.5.11.1 Point-of-Care Diagnosis of Infections

1.1.4.5.11.2 Positives and Negatives of Point-of-Care Diagnosis

1.1.4.5.12 Genetic Testing For Disease Predisposition

1.1.5 Analysis of Personalized Medicine by Technology

1.1.5.1 Pharmacogenomics

1.1.5.1.1 Drug Metabolism

1.1.5.1.2 Applications

1.1.5.2 Point-of-Care Testing

1.1.5.2.1 Tests that are Most Apt for Specific Scenarios

1.1.5.2.1.1 Primary Care

1.1.5.2.1.2 Emergency Room

1.1.5.2.1.3 Intensive Care

1.1.5.2.2 Advantages

1.1.5.3 Stem Cell Therapy

1.1.5.3.1 Treatment with Stem Cells

1.1.5.3.2 Current Therapies

1.1.5.3.3 Future Treatments

1.1.5.4 Pharmacoproteomics

1.1.5.5 Pharmacogenetics

1.1.5.5.1 Prediction of Drug-Drug Interactions

1.1.5.5.2 Integration of Pharmacogenetics with the Healthcare System

1.1.5.5.3 Pharmacogenetic Tests

1.1.5.5.4 Currently Used Tests

1.1.5.6 Other Personalized Medicine Technologies

1.1.5.6.1 Biochips

1.1.5.6.1.1 Fabrication of Microarrays

1.1.5.6.1.2 Protein Biochip Array and Other Microarray Technologies

1.1.5.6.1.3 Biochips Applications: Ranging from Diagnostics to Personalized

Medicine

1.1.5.6.2 Genetic Screening

1.1.5.6.2.1 Basic Screening

1.1.5.6.2.2 Screening Variations

1.1.5.6.2.3 Genetic Screening: Ethical Issues and Concerns

1.1.5.6.3 Metabolomics

1.1.5.6.4 Molecular Diagnostics

1.1.5.6.4.1 Molecular Diagnostics for Personalized Medicine

1.1.5.6.5 Pharmacodynamics

1.1.5.6.6 Pharmacokinetics

1.1.5.6.7 SNP Genotyping

1.1.5.6.7.1 Core Labs

1.1.5.6.7.2 Hybridization-Based Methods

1.1.5.6.7.3 Enzyme-Based Methods

1.1.5.6.7.4 Other Post-Amplification Methods Based on Physical Properties of DNA

1.1.6 The Rationale Behind Personalized Medicine: "One Size no Longer Fits All"

1.1.7 The Human Genome: What is It?

2. KEY MARKET TRENDS

Combating Melanoma and Lung Cancer Facilitated Using Novel Personalized Drugs
Personalized Medicine for Heart Patients Promised by University of Florida Academic Health Center

Personalized Medicine Integrated with Biosensors

Decade-Long Penn Medicine Study of HIV Patients Demonstrates Safety of Genetically Modified T Cell Therapy

Managing Infectious Diseases Using Point-of-Care Personalized Medicine Molecular Diagnostic Technologies

Introduction

Personalized Medicine and Infectious Diseases: An Unlikely Combination?

Universities to be Commended for Bringing Personalized Medicine to Patient Care

Nuclear Imaging Market to be Boosted through a Trend towards Personalized Medicine

Personalized Medicine for Lung Cancer Makes Progress

Micro RNA Denotes Response to Chemoprevention

Shorter Survival Predicted from RRM

Differentiating Tumor Types through Epigenetic Clues

Pharmaceutical and Diagnostic Company Business Models being Challenged by Personalized Medicine

Personalized Medicine and Pharmacogenomics: Single Nucleotide Polymorphisms' (SNPs) Role in Drug Therapy

Personalization of Medicine and the Role of SNPs

The Arrival of Pharmacogenetics and Illustrations of SNPs in Personalized Medicine

Personalized Medicine's Drawbacks in the Context of Genetic Discrimination

Personalized Medicine's Promise of Offering the Future Now

The Course of Advancements in Cancers

Live Healthy to Make a Difference

Personalized Medicine in Cancer Hits a Roadblock

Implications of Personalized Medicine for Pharmaceutical Manufacturers and Drug Development

Implications of Personalized Medicine

What Should Drug Developers Do

Is Drug Safety Capable of Being Improved through Personalized Medicine?

Personalized Medicine: A SWOT Analysis for Pharmacists

Strengths

Weaknesses

Opportunities

Threats

Genetic Testing for Identifying and Treating Specific Disorders

The Scientific and Commercial Facets of Personalized Medicine

Prevention and Treatment of Diabetes with Personalized Medicine

Medical Informatics and Personalized Medicine

Personalized Medicine for Treating Asthma

Personalized Medicine and Systems Engineering

The Evolving Role of CROs in Personalized Medicine

Personalized Medicine Being Guided by Stem Cell Therapies

Device Manufacturers Offered Better Prospects from the Trend Towards Personalized Medicine

3. KEY GLOBAL PLAYERS

4. KEY BUSINESS TRENDS

Lilly Partners with PrimeraDX for Novel Personalized Therapeutics
Sanofi Joins with Joslin Diabetes Center to Develop New Drugs
New Personalized Medicine Center to be Opened by PerkinElmer
Roche Signs Strategic Pact with Med Fusion
Agendia Introduces a New 18-Gene Expression Signature
Affymetrix Enters Research Collaboration with MGH
Affymetrix Signs Research Contract with Leica
Millennium Labs Launches Innovative Pharmacogenetic Test
Genedata Expressionist Opted for by Takeda
Boehringer Ingelheim and HealthRageous in an Agreement
Merck KGaA and MDxHealth Form Collaboration
FDA Approves Colorectal Cancer Companion Diagnostic from Qiagen
KineMed Collaborates with GSK for Biomarker Discovery
bioTheranostics Expands PR²CIS Biomarker Profiles
Quest Introduces New Molecular Test Panel
Biocartis Collaborates with Philips and Wellcome Trust
Agreement Signed between Immunexpress, Debiopharm, and Biocartis
Lab21 Signs Pact with Major Pharma Company to Develop Companion Diagnostic Assay
Clariant Acquires IP Rights for Developing ALK Biomarker Genetic Tests from Insight Genetics
Exosome Signs and Life Technologies Sign an Agreement
NextGen Commercializes Assay for New Diagnostics Biomarkers in Brain Disorders
Sanofi Collaborates with Joslin Diabetes Center
PerjetaTM (Pertuzumab) for People with HER2-Positive Metastatic Breast Cancer Granted FDA Approval
Software Re-enlisted by Roche for Personalized Medicine Research
Teva All Set to Enter Personalized Medicine Field
Personalized Medicine Test for ADHD Launched by AssureRx Health
XALKORI[®] Launched in Canada by Pfizer
Abbott Acquires License for Novel Biomarkers from Stanford
GE Bags SeqWright
PerkinElmer Unveils HER2Sense for Breast Cancer Research
Celgene Files FDA Application for Multiple Myeloma Drug

Takeda and Metabolon in a Partnership

Biomed Analytics Platform Tested by IBM in Association with Italian Institute

Abbott Joins Hands with Merck to Develop Companion Diagnostic Test

Chronix Biomedical Inaugurates State-of-the-Art Mass Sequencing Laboratory for Personal Biomarkers

Personalized Medicine Offered by IBM Genomic Analytics Platform

Clinical Genomics Centre Launched in USA by Lab21 and ITOR

GlaxoSmithKline and Epistem in an Agreement

Online Personalized Medicine Portal Launched by Cepmed

Dako Partners with Amgen to Develop Companion Diagnostic Test for Investigational Cancer Therapy

Personalized Medicine Partnership of Florida is to be Created

China's SFDA Approves First Microarray Instrument GCS 3000Dx v.2

Health Canada Approves First and Only Personalized Treatment for Deadliest Form of Skin Cancer

New Personalized Medicine Institute Launched by Moffitt Cancer Centre

Roche Bags EU Approval for Zelboraf

Amgen and Dako in an Alliance for Developing New Diagnostic Test for Cancer Therapy

Siemens Enters Personalized Medicine Field

Ventana Medical and Bayer Joins Forces to Develop Companion Diagnostic Test

AssureRx Launches GeneSightRx 1.8

bioTheranostics Unveils Precision Medicine Biomarkers

Identification of DNA Variants for Personalized Medicine Research by Ingenuity

Genzyme and Veracyte in an Agreement

OvaGene Joins Forces with Moffitt Cancer Center

GlaxoSmithKline and Abbott in Agreement to Expand Personalized Medicine for Cancer Diagnostic

Siemens and Illumina in a Partnership

Pfizer's Xalkori and Abbott Demonstrate a Bright Scope in Personalized Medicine, Companion Diagnostics

GNS Healthcare Collaborates with Bristol-Myers Squibb

Genetically Modified Human Cell Lines for Breast Cancer Research from Sigma® Life Science

Coriell Partners with IBM

QIAGEN Agrees to Acquire 61% Stake in Ipsogen

Joint Development of Biomarkers in Oncology by Roche and Evotec

Innovative COX-2 Probe Launched by Caliper Life Sciences

Caliper and Catholic Health Initiatives form Oncology Research Collaboration

Novel Patient-Specific Drug Targets Identified by GNS Healthcare and Biogen
Daiichi Sankyo Takes Over Plexxikon
Collaboration between Ipsen SA and BioMerieux SA in Personalized Medicine
AstraZeneca and HealthCore Form Collaboration
Minority Stake in Alacris Theranostics acquired by QIAGEN
GenomeQuest and Ingenuity Systems Form Partnership
Veridex and Massachusetts General Hospital Form Collaboration
Development of Personalized Medicine Further Accelerated with the Partnership
between Dako and Quintiles
First Pharmacogenomics Test Launched by Luminex Corp. for Personalized Medicine
Integration of Software between Ingenuity Systems and TransMed to Support
Personalized Medicine Research
Advancement of Personalized Medicine with the Launch of New Multiplex Tissue
Biomarker Technology
Personalized Medicine Brought to Market by Iris Biotechnologies

5. GLOBAL MARKET OVERVIEW

- 5.1 Market Overview by Product Type
- 5.2 Market Overview by Technology
- 5.3 Personalized Medicine Product Type Overview by Global Region
 - 5.3.1 Targeted Biologics
 - 5.3.2 Proteomics & Genomics
 - 5.3.3 Genetically Modified (GM) Products
 - 5.3.4 Wellness & Disease Management
 - 5.3.5 Other Molecular Diagnostic Products
 - 5.3.6 Self/Other Diagnostics
- 5.4 Personalized Medicine Technology Overview by Global Region
 - 5.4.1 Pharmacogenomics
 - 5.4.2 Point-of-Care Testing
 - 5.4.3 Stem Cell Therapy
 - 5.4.4 Pharmacoproteomics
 - 5.4.5 Pharmacogenetics
 - 5.4.6 Other Personalized Medicine Technologies

PART B: REGIONAL MARKET PERSPECTIVE

REGIONAL MARKET OVERVIEW

1. THE UNITED STATES

1.1 Market Overview by Product Type

1.2 Market Overview by Technology

1.3 Major Market Players

Abbott Laboratories, Inc.

Abbott Molecular Inc

Affymetrix, Inc.

Agilent Technologies, Inc.

Amgen, Inc.

Asuragen, Inc.

Baxter International Inc.

Beckman Coulter Genomics Inc.

Beckman Coulter, Inc.

BG Medicine, Inc.

Biogen Idec

Bristol-Myers Squibb Company

Caliper Life Sciences, Inc.

Celera Corporation

Celgene Corporation

Celldex Therapeutics

Cepheid

DNA Direct, Inc.

Eli Lilly and Company

Exact Sciences Corp.

Exagen Diagnostics, Inc.

Gene Logic

Genelex Corporation

Genentech, Inc.

Genomic Health Inc

Gen-Probe Incorporated

Genzyme Corporation

HistoRx, Inc.

Hologic Inc

Illumina, Inc.

Ingenuity Systems, Inc.

Johnson & Johnson

Laboratory Corporation of America (LABCORP)

Life Technologies Corporation

Luminex Corporation
Millennium Laboratories
Myriad Genetics, Inc.
PerkinElmer, Inc.
Pfizer Inc
Promega Corporation
Roche Diagnostics Corporation
Siemens Healthcare Diagnostics Inc.
Sigma-Aldrich Corporation
Thermo Fisher Scientific Inc
Ventana Medical Systems, Inc.

2. EUROPE

2.1 Market Overview by Product Type

2.2 Market Overview by Technology

2.3 Major Market Players

Agendia B.V. (The Netherlands)
AstraZeneca PLC (United Kingdom)
Bayer AG (Germany)
Bayer Healthcare AG (Germany)
Bayer Healthcare Pharmaceuticals (Germany)
Biocartis NV (Belgium)
Biocartis SA (Switzerland)
bioMérieux SA (France)
Boehringer Ingelheim GmbH (Germany)
Cytolon AG (Germany)
Dako A/S (Denmark)
Decode Genetics (Iceland)
Epistem Holdings PLC (United Kingdom)
Evotec AG (Germany)
GE Healthcare Ltd. (United Kingdom)
GlaxoSmithKline, PLC (United Kingdom)
Merck KGaA (Germany)
Novartis AG (Switzerland)
Qiagen N.V. (The Netherlands)
Roche Holding Ltd. (Switzerland)
Sanofi (France)
Siemens AG (Germany)

Siemens Healthcare (Germany)

The European Personalised Medicine Association (EPEMED) (Luxembourg)

3. REST OF WORLD

3.1 Market Overview by Product Type

3.2 Market Overview by Technology

3.3 Major Market Players

Astellas Pharma Inc. (Japan)

Cepmed (Canada)

Daiichi Sankyo Company Limited (Japan)

DNA Genotek Inc. (Canada)

Mitsubishi Tanabe Pharma Corporation (Japan)

Rosetta Genomics Ltd. (Israel)

Teva Pharmaceutical Industries Ltd. (Israel)

Takeda Pharmaceutical Company Limited (Japan)

PART C: GUIDE TO THE INDUSTRY

1. NORTH AMERICA

1.1 Canada

1.2 United States

2. EUROPE

2.1 Austria

2.2 Belgium

2.3 Denmark

2.4 France

2.5 Germany

2.6 Iceland

2.7 Ireland

2.8 Italy

2.9 Luxembourg

2.10 Spain

2.11 Switzerland

2.12 The Netherlands

2.13 United Kingdom

3. ASIA-PACIFIC

- 3.1 Australia
- 3.2 China
- 3.3 Hong Kong
- 3.4 Japan
- 3.5 New Zealand
- 3.6 South Korea
- 3.7 Taiwan

4. REST OF WORLD

- 4.1 Israel

5. RESEARCH & EDUCATIONAL INSTITUTIONS

PART D: ANNEXURE

1. RESEARCH METHODOLOGY

2. FEEDBACK

CHARTS & GRAPHS

PART A: GLOBAL MARKET PERSPECTIVE

Chart 1: Global Personalized Medicine Market Analysis (2008-2018) in USD Million

Chart 2: Global Personalized Medicine Market Analysis (2008-2018) by Product Type – Targeted Biologics, Proteomics & Genomics, Genetically Modified (GM) Products, Wellness & Disease Management, Other Molecular Diagnostics and Self/Other Diagnostics in USD Million

Chart 3: Glance at 2008, 2013 and 2018 Global Personalized Medicine Market Share (%) by Product Type – Targeted Biologics, Proteomics & Genomics, Genetically Modified (GM) Products, Wellness & Disease Management, Other Molecular Diagnostics and Self/Other Diagnostics

Chart 4: Global Personalized Medicine Market Analysis (2008-2018) by Technology – Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other Technologies in USD Million

Chart 5: Glance at 2008, 2013 and 2018 Global Personalized Medicine Market Share

(%) by Technology – Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other Technologies

Chart 6: Global Market Analysis of Targeted Biologics in Personalized Medicine (2008-2018) by Geographic Region – United States, Europe and Rest of World in USD Million

Chart 7: Glance at 2008, 2013 and 2018 Global Market Share (%) of Targeted Biologics in Personalized Medicine by Geographic Region – United States, Europe and Rest of World

Chart 8: Global Market Analysis of Proteomics & Genomics in Personalized Medicine (2008-2018) by Geographic Region – United States, Europe and Rest of World in USD Million

Chart 9: Glance at 2008, 2013 and 2018 Global Market Share (%) of Proteomics & Genomics in Personalized Medicine by Geographic Region – United States, Europe and Rest of World

Chart 10: Global Market Analysis of Genetically Modified (GM) Products in Personalized Medicine (2008-2018) by Geographic Region – United States, Europe and Rest of World in USD Million

Chart 11: Glance at 2008, 2013 and 2018 Global Market Share (%) of Genetically Modified (GM) Products in Personalized Medicine by Geographic Region – United States, Europe and Rest of World

Chart 12: Global Market Analysis of Wellness & Disease Management in Personalized Medicine (2008-2018) by Geographic Region – United States, Europe and Rest of World in USD Million

Chart 13: Glance at 2008, 2013 and 2018 Global Market Share (%) of Wellness & Disease Management in Personalized Medicine by Geographic Region – United States, Europe and Rest of World

Chart 14: Global Market Analysis of Other Molecular Diagnostics in Personalized Medicine (2008-2018) by Geographic Region – United States, Europe and Rest of World in USD Million

Chart 15: Glance at 2008, 2013 and 2018 Global Market Share (%) of Other Molecular Diagnostics in Personalized Medicine by Geographic Region – United States, Europe and Rest of World

Chart 16: Global Market Analysis of Self/Other Diagnostics in Personalized Medicine (2008-2018) by Geographic Region – United States, Europe and Rest of World in USD Million

Chart 17: Glance at 2008, 2013 and 2018 Global Market Share (%) of Self/Other Diagnostics in Personalized Medicine by Geographic Region – United States, Europe and Rest of World

Chart 18: Global Market Analysis of Pharmacogenomics in Personalized Medicine

(2008-2018) Geographic Region – United States, Europe and Rest of World in USD Million

Chart 19: Glance at 2008, 2013 and 2018 Global Market Share (%) of Pharmacogenomics in Personalized Medicine by Geographic Region – United States, Europe and Rest of World

Chart 20: Global Market Analysis of Point-of-Care Testing in Personalized Medicine (2008-2018) Geographic Region – United States, Europe and Rest of World in USD Million

Chart 21: Glance at 2008, 2013 and 2018 Global Market Share (%) of Point-of-Care Testing in Personalized Medicine by Geographic Region – United States, Europe and Rest of World

Chart 22: Global Market Analysis of Stem Cell Therapy in Personalized Medicine (2008-2018) Geographic Region – United States, Europe and Rest of World in USD Million

Chart 23: Glance at 2008, 2013 and 2018 Global Market Share (%) of Stem Cell Therapy in Personalized Medicine by Geographic Region – United States, Europe and Rest of World

Chart 24: Global Market Analysis of Pharmacoproteomics in Personalized Medicine (2008-2018) Geographic Region – United States, Europe and Rest of World in USD Million

Chart 25: Glance at 2008, 2013 and 2018 Global Market Share (%) of Pharmacoproteomics in Personalized Medicine by Geographic Region – United States, Europe and Rest of World

Chart 26: Global Market Analysis of Pharmacogenetics in Personalized Medicine (2008-2018) Geographic Region – United States, Europe and Rest of World in USD Million

Chart 27: Glance at 2008, 2013 and 2018 Global Market Share (%) of Pharmacogenetics in Personalized Medicine by Geographic Region – United States, Europe and Rest of World

Chart 28: Global Market Analysis of Other Personalized Medicine Technologies (2008-2018) Geographic Region – United States, Europe and Rest of World in USD Million

Chart 29: Glance at 2008, 2013 and 2018 Global Market Share (%) of Other Personalized Medicine Technologies by Geographic Region – United States, Europe and Rest of World

PART B: REGIONAL MARKET PERSPECTIVE

Chart 30: Global Personalized Medicine Market Analysis (2008-2018) by Geographic Region – United States, Europe and Rest of World in USD Million

Chart 31: Glance at 2008, 2013 and 2018 Global Personalized Medicine Market Share (%) by Geographic Region – United States, Europe and Rest of World

REGIONAL MARKET OVERVIEW

THE UNITED STATES

Chart 32: United States Personalized Medicine Market Analysis (2008-2018) by Product Type – Targeted Biologics, Proteomics & Genomics, Genetically Modified (GM) Products, Wellness & Disease Management, Other Molecular Diagnostics and Self/Other Diagnostics in USD Million

Chart 33: Glance at 2008, 2013 and 2018 United States Personalized Medicine Market Share (%) by Product Type – Targeted Biologics, Proteomics & Genomics, Genetically Modified (GM) Products, Wellness & Disease Management, Other Molecular Diagnostics and Self/Other Diagnostics

Chart 34: United States Personalized Medicine Market Analysis (2008-2018) by Technology – Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other Technologies in USD Million

Chart 35: Glance at 2008, 2013 and 2018 United States Personalized Medicine Market Share (%) by Technology – Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other Technologies

EUROPE

Chart 36: European Personalized Medicine Market Analysis (2008-2018) by Product Type – Targeted Biologics, Proteomics & Genomics, Genetically Modified (GM) Products, Wellness & Disease Management, Other Molecular Diagnostics and Self/Other Diagnostics in USD Million

Chart 37: Glance at 2008, 2013 and 2018 European Personalized Medicine Market Share (%) by Product Type – Targeted Biologics, Proteomics & Genomics, Genetically Modified (GM) Products, Wellness & Disease Management, Other Molecular Diagnostics and Self/Other Diagnostics

Chart 38: European Personalized Medicine Market Analysis (2008-2018) by Technology – Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other Technologies in USD Million

Chart 39: Glance at 2008, 2013 and 2018 European Personalized Medicine Market Share (%) by Technology – Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other Technologies

REST OF WORLD

Chart 40: Rest of World Personalized Medicine Market Analysis (2008-2018) by Product

Type – Targeted Biologics, Proteomics & Genomics, Genetically Modified (GM) Products, Wellness & Disease Management, Other Molecular Diagnostics and Self/Other Diagnostics in USD Million

Chart 41: Glance at 2008, 2013 and 2018 Rest of World Personalized Medicine Market Share (%) by Product Type – Targeted Biologics, Proteomics & Genomics, Genetically Modified (GM) Products, Wellness & Disease Management, Other Molecular Diagnostics and Self/Other Diagnostics

Chart 42: Rest of World Personalized Medicine Market Analysis (2008-2018) by Technology – Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other Technologies in USD Million

Chart 43: Glance at 2008, 2013 and 2018 Rest of World Personalized Medicine Market Share (%) by Technology – Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other Technologies

I would like to order

Product name: Personalized Medicine - A Global Market Overview

Product link: <https://marketpublishers.com/r/PB5DCD6A2A8EN.html>

Price: US\$ 3,600.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PB5DCD6A2A8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970